Orthopeutics Group, LLC
Records under this name other than patents Orthopeutics Group, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Orthopeutics Group, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,278,947 | Crosslinker Enhanced Repair of Connective Tissues Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,283,322 | Formulations for nonsurgical exogenous crosslink therapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,198,248 | Formulations for nonsurgical exogenous crosslink therapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,084,772 | Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,119,599 | Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity Formerly held Term ended Term ended Apr 1, 2025 · From the USPTO record | Term ended | Term ended Apr 1, 2025 | From the USPTO record |
| US 7,435,722 | Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability Formerly held Term ended Term ended Jan 19, 2025 · From the USPTO record | Term ended | Term ended Jan 19, 2025 | From the USPTO record |
| US 9,101,602 | Use of Non-Toxic Crosslinking Reagents to Improve Fatigue Resistance and Reduce Mechanical Degradation of Intervertebral Disc and Other Collagenous Tissues Formerly held Term ended Ended no later than Mar 16, 2024 · Medium confidence | Term ended | Ended no later than Mar 16, 2024 | Medium confidence |
| US 8,450,276 | Non-Toxic Crosslinking Reagents to Resist Curve Progression in Scoliosis and Increase Disc Permeability Formerly held Term ended Ended no later than Aug 1, 2023 · Low confidence | Term ended | Ended no later than Aug 1, 2023 | Low confidence |
| US 8,211,938 | Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity Formerly held Term ended Term ended May 7, 2023 · From the USPTO record | Term ended | Term ended May 7, 2023 | From the USPTO record |
| US 9,192,507 | Tissue crosslinking for treatment of snoring and obstructive sleep apnea Formerly held Term ended Term ended Jan 6, 2023 · From the USPTO record | Term ended | Term ended Jan 6, 2023 | From the USPTO record |